Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 20, 2025Deleted Journal

Luspatercept (REBLOZYL): A Game-Changer in Reducing Transfusion Burden for β-Thalassemia Patients

View Full Paper
Ask AI
Bookmark
Share

Authors

AAAman AdvaniSMSaad Ahmed Mughal

Discussion

Loading...

Member takes

Overview

Clinical trials support luspatercept’s efficacy in decreasing transfusion burden in β-thalassemia patients, suggesting significant quality of life improvements.

Key Points

  • Luspatercept effectively decreases the transfusion burden in β-thalassemia patients, enhancing their quality of life.
  • Clinical trials, including the BELIEVE trial, confirmed reduced transfusion needs, showing a positive impact on patient health.
  • Luspatercept acts on the TGF-β superfamily, aiding late-stage erythroid maturation to combat transfusion dependence.
  • Caution is advised regarding potential side effects such as bone pain and the contraindication in patients with active extramedullary hematopoiesis.

Cite This Study

Advani et al. (2025) studied this question.

synapsesocial.com/papers/68d46fcd31b076d99fa69df9https://doi.org/10.62497/irabcs.150
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Outcomes with luspatercept in patients with β-thalassemia: a systematic review and meta-analysis2026
  2. 2Luspatercept in β-thalassemia: Meta-analysis of efficacy and safety across transfusion-dependent and non-transfusion-dependent populations2025
  3. 3LUSPATERCEPT – AN INNOVATIVE APPROACH TO THE TREATMENT OF ANEMIA IN BETA-THALASSEMIA AND MYELODYSPLASTIC SYNDROMES2025
  4. 4Efficacy of luspatercept in reducing transfusion burden and its impact on liver iron concentration in beta-thalassemia major: A systematic review and meta-analysis2025
  5. 5Outcomes with luspatercept in patients with β-thalassemia: A systematic review and meta-analysis2025